c_Jun (Phospho_Ser63) Antibody
- Known as:
- c_Jun (Phospho_Ser63) Antibody
- Catalog number:
- E011001-2
- Product Quantity:
- 100ug
- Category:
- Antibodies
- Supplier:
- EnoGene
- Gene target:
- c_Jun (Phospho_Ser63) Antibody
Related products to: c_Jun (Phospho_Ser63) Antibody
Related articles to: c_Jun (Phospho_Ser63) Antibody
- Pediatric cerebral venous sinus thrombosis (CVST) is being increasingly recognized and can pose substantial risks of morbidity and mortality. Data on the epidemiology, management, and outcomes of CVST in the PICU remain limited. - Source: PubMed
Publication date: 2026/05/25
Maratta ChristinaGaetani MelanyMcKinnon Nicole KAnthony DavidMasood SahrishPulcine ElizabethMtaweh Haifa - High dietary carbohydrate (CHO) intake and reduced exercise training are recommended to optimize muscle glycogen stores pre-endurance sports competition. However, the optimal CHO intake to support muscle glycogen synthesis and the dose-response of this relationship are still unknown in athletes who continue training pre-competition. This study investigated the effects of different CHO intakes on muscle glycogen concentration. In a counterbalanced repeated measures design, 11 endurance-trained participants (3 females, 8 males; age, 24 ± 5 years; body mass, 71.2 ± 12.0 kg; V̇O, 56 ± 6 mL kg min) undertook 3 × 5 days of exercise and dietary control. During the final 48 h, participants ingested 6, 8 or 10 g kg day CHO prior to the assessment of muscle glycogen, gastrointestinal (GI) comfort and body composition. Muscle glycogen concentration was significantly higher following 10 vs. 6 and 8 g kg day (635.5 ± 78.0 vs. 460.9 ± 100.7 and 506.1 ± 124.0 mmol kg dry mass, respectively, p < 0.03), with no difference between 6 and 8 g kg day (p = 1.00). There was a strong positive correlation between relative CHO intake (r = 0.71, p < 0.001) and skeletal muscle glycogen concentration. There was no effect of CHO intake on body mass (p = 0.70) or GI symptoms (p > 0.05), except fullness. In conclusion, there was a linear dose-response between dietary CHO intake and muscle glycogen in a protocol mimicking real-world training and nutrition practices, as 10 g kg day achieved the highest muscle glycogen concentrations, with no detectable effect on body mass or GI symptoms, except increased fullness. - Source: PubMed
Jones Robyn OAreta José LBennett SamuelPugh JamieLouis Julien B - Low physical activity (PA) and fitness in childhood are linked to adverse health outcomes, yet many Danish children do not meet national guidelines. The FIT FIRST 10 (FF10) multisport PE programme was developed to increase PA in primary schools. To evaluate dose-response effects of a 4-month FF10 intervention on physical fitness and psychosocial well-being. Three-arm, cluster-randomized trial (1:1:1). 1357 pupils (7-11 years) from 68 classes in 27 schools were allocated to control (CON, n = 529), 1.5 FF10 sessions/week (1.5INT, n = 495), or 3 FF10 sessions/week (3INT, n = 333); 1175 provided consent. The primary outcome was cardiorespiratory fitness via the Yo-Yo Intermittent Recovery Level 1 Children's test (YYIR1C). Secondary outcomes included cardiometabolic health, muscular fitness, and psychosocial well-being. No between-group effects were observed for the primary outcome (1.5INT vs. CON: 17 m [-19, 52]; 3INT vs. CON: -8 m [-47, 31]). Among secondary outcomes, 1.5INT showed small favorable effects on body composition (body fat percentage -0.4%; fat mass -0.2 kg; fat mass index -0.1 kg/m; BMI -0.1 kg/m) and handgrip strength (+0.4 kg) (all p < 0.05). No intervention effects were observed for cardiovascular or psychosocial domains. Small differences favoring CON over 3INT emerged in standing long jump (-5 cm), postural balance (-0.5 s) and perceived flexibility (-0.3 AU) (all p < 0.05). In conclusion, a moderate, feasible dose of approximately 1.5 FF10 sessions per week appeared more effective than a higher-frequency implementation, highlighting the importance of feasibility and implementation fidelity in real-world school settings. ClinicalTrials.gov (NCT06180772). - Source: PubMed
Eckert CarolineThøgersen-Ntoumani CecilieLarsen Malte NejstKoch SofieChristiansen Lars BreumMeiner Christina BirchCimenti ChiaraTarantino GiampieroNtoumanis NikosKrustrup Peter - Esophageal cancer (EC) is one of the most aggressive malignancies with limited therapeutic options and poor prognosis. Astragalus membranaceus (AM), a traditional Chinese herbal medicine with established immunomodulatory properties, has demonstrated anti-tumor potential, but its systematic immunomodulatory mechanisms in EC remain unclear. Here, we employed an integrative strategy combining network pharmacology, survival analysis, and molecular dynamics simulation to elucidate AM's immunotherapeutic mechanisms in EC. We identified 17 active compounds from AM and 445 target genes associated with them, Among these, 113 were classified as immune target genes (ITGs) with potential relevance to EC. Functional enrichment analysis revealed significant involvement of ITGs in TNF signaling, PI3K-AKT signaling, and PD-L1/PD-1 checkpoint pathways.The prognostic model constructed by five ITGs (AHR, AKT1, GPER1, IL4, and MAPK1) can be used as a reliable prognostic feature of EC and was validated in an independent cohort. Protein-protein interaction analysis identified eight core ITGs (TNF, RELA, IL6, NFKB1, JUN, AKT1, TP53, and IL1β) significantly associated with immune cell infiltration, immune checkpoint expression, and immunotherapy response. Molecular docking and molecular dynamics simulation confirmed stable binding of isorhamnetin to AKT1, revealing key interaction residues. These findings suggested the multi-compound, multi-target, and multi-pathway immunomodulatory mechanism of AM in EC, providing a prognostic tool for patient stratification and identifying the isorhamnetin-AKT1 axis as a potential therapeutic target. - Source: PubMed
Publication date: 2026/05/25
Zheng YonglangChen JianghuaChen ChenChen KunPan MeitongJia Lihua - - Source: PubMed
Abe Hiroya